Recruiting
Neoplasm malignant+7
RecruitingStudy on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors
Registered drugNo placebo
Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors
Registered drugNo placebo
- Disease:Neoplasm malignantNeoplasm+6
- Substances:IpilimumabNivolumab+2
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Ipilimumab
- Sponsor:Exelixis Inc.



